GI Stool Testing (FOBT & Clinical Microbiology Stool Test) Market 2015-2019 with Clinical Genomics, Diasorin, Meridian Bioscience & Quidel Dominating

Dec 14, 2015, 04:30 ET from Research and Markets

DUBLIN, December 14, 2015 /PRNewswire/ --

Research and Markets ( has announced the addition of the "GI Stool Testing Market 2015-2019 - Global Market Research" report to their offering.

     (Logo: )

The global GI stool testing market is expected to grow at a CAGR of 7.37% during 2014-2019

The report, Global GI Stool Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global BI and analytics platform market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Stool tests are used for the diagnosis of GI disorders and help detect parasite infection, inflammation, bleeding obstruction, and tumors in the GI tract and digestive system. The diagnosis of GI diseases is commonly done through laboratory tests using antigen or culture detection from stool samples. A stool test is of two categories: fecal occult blood test (FOBT) and clinical microbiological stool tests. These tests are either antibody-based or microbial particle-based detection methods, which include immunoassay, CLIA, and molecular diagnostic testing. Stool tests are used for the screening of colorectal cancer as well as the detection of pathogens such as C. difficile, H. pylora, Rotavirus, and Adenovirus. 

Point-of-care diagnostic tests for infectious diseases and cancer can be performed at or near the site of patient care. These tests offer patients timely access to care and treatment, reducing the overall probability of disease transmission.

According to the report, many companies are expanding into emerging countries, such as India, China, and Brazil, as these economies have significant growth potential. The implementation of government initiatives to build healthcare infrastructure, increase healthcare budgets, and advance technology propel market growth in these countries.

Further, the report states that gastrointestinal stool tests face stiff competition from their alternatives. Stool tests such as FIT can sometimes give false positive or negative results during colorectal cancer screening. In comparison, colonoscopy and CT colonography tests provide accurate results. For this reason, many medical professionals prefer these procedures to stool tests for the detection of colorectal cancer.

Key vendors

  • Clinical Genomics
  • Diasorin
  • Meridian Bioscience
  • Quidel

Other prominent vendors 

  • Alere
  • Beckman Coulter
  • bioMérieux
  • Bio-Rad Laboratories
  • CARE Products
  • Cenogenics
  • Epigenomics
  • Epitope Diagnostic
  • Exact Sciences
  • Helena Laboratories
  • Hemosure
  • Mobidiag
  • Orion Diagnostica
  • Pinnacle BioLabs
  • Polymedco
  • Propper Manufacturing
  • ScheBo Biotech
  • Trinity Biotech

Key Topics Covered: 

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Reimbursement and coverage: An overview

Part 07: Gastrointestinal stool tests: Present and future technology

Part 08: Market segmentation by product

Part 09: Market segmentation by application

Part 10: Market segmentation by technology

Part 11: Market segmentation by test

Part 12: Geographical segmentation

Part 13: Market drivers

Part 14: Impact of drivers

Part 15: Market challenges

Part 16: Impact of drivers and challenges

Part 17: Market trends

Part 18: Vendor landscape

Part 19: Key vendor analysis

For more information visit

About Research and Markets:  

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Laura Wood,

SOURCE Research and Markets